Advertisement
Advertisement
BMRN
BioMarin Pharmaceuticals Inc
61.70
USDSponsored
+0.59
+0.97%
Feb 27, 15:59 UTC -5
Closed
After-Market
59.27
-2.43
-3.94%
BMRN Earnings Reports
Positive Surprise Ratio
BMRN beat 29 of 41 last estimates.
71%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$835.65M
/$1.09
Implied change from Q4 25 (Revenue/ EPS)
-4.45%
/+136.96%
Implied change from Q1 25 (Revenue/ EPS)
+12.15%
/+14.74%
BioMarin Pharmaceuticals Inc earnings per share and revenue
On Feb 23, 2026, BMRN reported earnings of 0.46 USD per share (EPS) for Q4 25, missing the estimate of 0.63 USD, resulting in a -27.79% surprise. Revenue reached 874.57 million, compared to an expected 844.44 million, with a 3.57% difference. The market reacted with a -0.48% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 17 analysts forecast an EPS of 1.09 USD, with revenue projected to reach 835.65 million USD, implying an increase of 136.96% EPS, and decrease of -4.45% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
argenx SE - ADR
Report Date
Feb 26, 2026 For Q4 25
Estimate
$6.23
Actual
$8.02
Surprise
+28.67%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Feb 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-10.54%
ANI Pharmaceuticals, Inc.
Report Date
Feb 27, 2026 For Q4 25
Estimate
$2.03
Actual
$2.33
Surprise
+14.48%
Novavax Inc
Report Date
Feb 26, 2026 For Q4 25
Estimate
-$0.49
Actual
$0.11
Surprise
+122.02%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Feb 26, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.08
Surprise
+79.44%
Pacira BioSciences, Inc. Common Stock
Report Date
Feb 26, 2026 For Q4 25
Estimate
$0.92
Actual
$0.56
Surprise
-38.21%
Emergent Biosolutions, Inc.
Report Date
Feb 26, 2026 For Q4 25
Estimate
$0.11
Actual
-$0.43
Surprise
-487.04%
PUMA BIOTECHNOLOGY INC
Report Date
Feb 26, 2026 For Q4 25
Estimate
$0.23
Actual
$0.28
Surprise
+25.27%
Anika Therapeutics Inc
Report Date
Feb 26, 2026 For Q4 25
Estimate
-$0.21
Actual
$0.31
Surprise
+241.36%
ALX Oncology Holdings Inc. Common Stock
Report Date
Feb 27, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.61%
FAQ
What were BioMarin Pharmaceuticals Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, BioMarin Pharmaceuticals Inc reported EPS of $0.46, missing estimates by -27.79%, and revenue of $874.57M, 3.57% above expectations.
How did the market react to BioMarin Pharmaceuticals Inc's Q4 2025 earnings?
The stock price moved down -0.48%, changed from $62.92 before the earnings release to $62.62 the day after.
When is BioMarin Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for BioMarin Pharmaceuticals Inc's next earnings report?
Based on 17
analysts, BioMarin Pharmaceuticals Inc is expected to report EPS of $1.09 and revenue of $835.65M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement